These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26309431)

  • 1. Relation of Osteoprotegerin, Visfatin and Ghrelin to Metabolic Syndrome in Type 2 Diabetic Patients.
    Ahmed MB; Ismail MI; Meki AR
    Int J Health Sci (Qassim); 2015 Apr; 9(2):127-39. PubMed ID: 26309431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of atorvastatin on apelin, visfatin (nampt), ghrelin and early carotid atherosclerosis in patients with type 2 diabetes.
    Kadoglou NP; Sailer N; Kapelouzou A; Lampropoulos S; Vitta I; Kostakis A; Liapis CD
    Acta Diabetol; 2012 Aug; 49(4):269-76. PubMed ID: 21748474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes.
    Kadoglou NP; Sailer N; Moumtzouoglou A; Kapelouzou A; Tsanikidis H; Vitta I; Karkos C; Karayannacos PE; Gerasimidis T; Liapis CD
    Exp Clin Endocrinol Diabetes; 2010 Feb; 118(2):75-80. PubMed ID: 19834878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus.
    Kadoglou NP; Tsanikidis H; Kapelouzou A; Vrabas I; Vitta I; Karayannacos PE; Liapis CD; Sailer N
    Metabolism; 2010 Mar; 59(3):373-9. PubMed ID: 19815243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum visfatin and its relation to insulin resistance and inflammation in type 2 diabetic patients with and without macroangiopathy.
    Alghasham AA; Barakat YA
    Saudi Med J; 2008 Feb; 29(2):185-92. PubMed ID: 18246224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visfatin in obese children and adolescents and its association with insulin resistance and metabolic syndrome.
    Nourbakhsh M; Nourbakhsh M; Gholinejad Z; Razzaghy-Azar M
    Scand J Clin Lab Invest; 2015 Apr; 75(2):183-8. PubMed ID: 25723377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome.
    Chedraui P; Pérez-López FR; Escobar GS; Palla G; Montt-Guevara M; Cecchi E; Genazzani AR; Simoncini T;
    Maturitas; 2014 Sep; 79(1):86-90. PubMed ID: 25015014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Association between both resistin, visfatin and insulin resistance as well as β cell function in the first-degree relatives of type 2 diabetes mellitus].
    Zhang XJ; Wang Z; Li HH; Yu L; Gao S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Dec; 31(12):1393-6. PubMed ID: 21223671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Salivary Adipokines Resistin, Visfatin, and Ghrelin as Type 2 Diabetes Mellitus Biomarkers.
    Srinivasan M; Meadows ML; Maxwell L
    Biochem Res Int; 2018; 2018():7463796. PubMed ID: 29487749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased plasma levels of visfatin/pre-B cell colony-enhancing factor in obese and overweight patients with metabolic syndrome.
    Filippatos TD; Derdemezis CS; Kiortsis DN; Tselepis AD; Elisaf MS
    J Endocrinol Invest; 2007 Apr; 30(4):323-6. PubMed ID: 17556870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum visfatin and fetuin-a levels and glycemic control in patients with obese type 2 diabetes mellitus.
    Gunduz FO; Yildirmak ST; Temizel M; Faki Y; Cakmak M; Durmuscan M; Sezgin F
    Diabetes Metab J; 2011 Oct; 35(5):523-8. PubMed ID: 22111044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated visfatin levels in overweight and obese children and adolescents with metabolic syndrome.
    Kolsgaard ML; Wangensteen T; Brunborg C; Joner G; Holven KB; Halvorsen B; Aukrust P; Tonstad S
    Scand J Clin Lab Invest; 2009; 69(8):858-64. PubMed ID: 19929281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis.
    Zhong M; Tan HW; Gong HP; Wang SF; Zhang Y; Zhang W
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):878-84. PubMed ID: 18363885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.
    Chen MP; Chung FM; Chang DM; Tsai JC; Huang HF; Shin SJ; Lee YJ
    J Clin Endocrinol Metab; 2006 Jan; 91(1):295-9. PubMed ID: 16234302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severity of the metabolic syndrome as a predictor of prediabetes and type 2 diabetes in first degree relatives of type 2 diabetic patients: A 15-year prospective cohort study.
    Meamar R; Amini M; Aminorroaya A; Nasri M; Abyar M; Feizi A
    World J Diabetes; 2020 May; 11(5):202-212. PubMed ID: 32477456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The difference in correlation between insulin resistance index and chronic inflammation in type 2 diabetes with and without metabolic syndrome.
    Pourfarzam M; Zadhoush F; Sadeghi M
    Adv Biomed Res; 2016; 5():153. PubMed ID: 27713874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of glucagon-like peptide-1 analogue; Exendin-4, on cognitive functions in type 2 diabetes mellitus; possible modulation of brain derived neurotrophic factor and brain Visfatin.
    Abdelwahed OM; Tork OM; Gamal El Din MM; Rashed L; Zickri M
    Brain Res Bull; 2018 May; 139():67-80. PubMed ID: 29421245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin resistance-related circulating predictive markers in the metabolic syndrome: a systematic review in the Iranian population.
    Zahedi AS; Zarkesh M; Sedaghati-Khayat B; Hedayati M; Azizi F; Daneshpour MS
    J Diabetes Metab Disord; 2024 Jun; 23(1):199-213. PubMed ID: 38932859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.
    Barchetta I; Ceccarelli V; Cimini FA; Bertoccini L; Fraioli A; Alessandri C; Lenzi A; Baroni MG; Cavallo MG
    J Endocrinol Invest; 2019 May; 42(5):513-520. PubMed ID: 30132286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compare the effects of different visfatin concentration on cardiovascular risk factors, adiponectin and insulin resistance in patients with T2DM.
    Mohammadi S; Hosseinzadeh-Attar MJ; Hosseinnezhad A; Hosseini SH; Eshraghian MR; Nezhad MK; Rahmani M; Karimi M
    Diabetes Metab Syndr; 2011; 5(2):71-5. PubMed ID: 22813406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.